Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study

BACKGROUND: Neutropenia is a common toxicity in patients receiving myelosuppressive chemotherapy. In this prospective pilot study, we compared the efficacy and safety profiles of pegfilgrastim administered subcutaneously once per cycle and lenograstim administered subcutaneously daily six times per...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigi, Tomao, Federica, Lo Russo, Giuseppe, Papa, Anselmo, Zoratto, Federica, Marzano, Raffaella, Basso, Enrico, Giordani, Erika, Verrico, Monica, Ricci, Fabio, Pasciuti, Giulia, Francini, Edoardo, Tomao, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832460/
https://www.ncbi.nlm.nih.gov/pubmed/24255599
http://dx.doi.org/10.2147/TCRM.S48387

Ejemplares similares

Ejemplares similares